Consistent with Pan‐cancer analysis (An et al, 2019), analysis of patient survival showed that higher MB21D1 expression led to worst patient survival as compared to patients with low MB21D1 expression, supporting that expression of cGAS is a poor outcome marker in glioblastoma (Fig 6G). The gene discussed is CGAS; the disease is cancer.